A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly
Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)
Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
PASI 75 response over time in FIXTURE study. 3 Green and orange arrows... | Download Scientific Diagram
Evolution of psoriasis endpoint use - IQVIA
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
Major Secondary Endpoints: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial | PLOS ONE
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Data from the Otezla ESTEEM Clinical Trial | Otezla® (apremilast) Healthcare Professional Site
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Novartis' Cosentyx™ two-year data shows sustained effect and favorable safety profile in psoriasis patients | Novartis
VOYAGE 1: Moderate to Severe PsO | TREMFYA® (guselkumab) HCP
Proportions of patients who achieved (a) PASI-75 and (b) PASI-50 and... | Download Scientific Diagram
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
